Dermaxon
  • Home
  • About Us
    • Contact
  • News
  • Science
  • Our Technologies
    • The human brain
    • Skin
    • Pain
  • Pipeline
Select Page

Characterization of CYP26B1-selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders.

Background: Retinoid-based therapies are commonly used in the treatment of disorders of keratinization and other skin disorders but can result in non-specific effects and adverse reactions. Use of retinoic acid metabolism blocking agents (RAMBAs) such as DX308 may...
  • Facebook
  • RSS

Copyright, Dermaxon. All rights reserved.